Marc and team's incompetence is a serious detriment to SP. Missteps on cash raises and dilution. Unable to generate outside revenue taking money from long term holders. Send them packing vote them out. Saying that we have a case to help people and male big money.
What the FDA Cares AboutThe FDA evaluates drugs on three main axes:Efficacy (clear benefit)Safety (especially compared to alternatives)Unmet need (especially for hard-to-treat populations)➡️ Efti hits all three:one of the safest + most effective IO combinations in development right now. If upcoming data stay consistent, it will be very hard for the FDA to say no, especially for patient groups with few optionsWorks better than pembrolizumab alone in PD-L1–low/negative NSCLC and HNSCC patientsFar safer than most dual checkpoint regimens
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $381.6M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 26.5¢ | 25.0¢ | $522.2K | 2.030M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 89000 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 3997 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |